Universidad Veracruzana a public autonomous university located in the Mexican state of Veracruz. Established in 1944, the university is one of the most important in the south-east region of México and has a good projection in all México. Its academic organization is a structure based on academic areas, schools, education programs and research institutes. Due to geographic dispersing, academic activities are coordinated by the Academic Secretariat and four Vice-Rector’s Offices. General Directions of the academic areas: Arts, Biology and Agricultural science, Health science, Economics and Business Administration, Liberal Arts and Technical coordinate as well each school and educational programs. The Department of Research coordinates the plans and activities of the research institutes, and the Direction of Art Dissemination operates the artistic groups and the cultural activities programs.In the region of Xalapa, the University has 32 schools, 22 institutes and research centers, one Children’s Musical Induction Center, one Language Center, one Foreign Languages Department, two Self-access Language Learning Centers, two Arts Workshops, one Foreign Students School, one Advanced Technology Lab, one Analytic Resolution Support Services Unit, one School Hospital and one Library Services and Information Unit . In Veracruz: 13 schools, four institutes and research centers, one Children’s Musical Induction Center, one Language Center, two Self-access Language Learning Centers, one Art Workshops and one USBI. In Orizaba-Córdoba: 8 schools, two Language Centers, two Self-access Language Learning Centers and an Advanced Technology Lab. In Poza Rica: 13 schools, one Language Center, a Self-access Language Learning Center, and two Art Workshops. And in Coatzacoalcos-Minatitlán, 8 schools, one Language Center, two Self-access Learning Centers and two USBIs. Furthermore, it is associated with the North American Mobility Project, a transnational academic program that links it to Georgia Southern University in the United States and Wilfrid Laurier University in Canada. Wikipedia.
News Article | December 7, 2016
PRINCETON, N.J., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that preclinical data on the potential use of detoxified Listeriolysin O (dtLLO) as an effective adjuvant for the development of infectious disease vaccines will be presented at the 11th annual ImVacS-Immunization and Vaccine Summit in Boston on Dec. 9. Dr. Hector Vivanco Cid, of the Institute of Medical Biological Research at the University of Veracruz in Mexico, is presenting data that supports the use of dtLLO as a potential immunologic adjuvant or carrier for vaccinations. dtLLO successfully induced high levels of specific igG antibodies against a selected Dengue virus protein in a preclinical model, in addition to demonstrating safety in vivo, highlighting its potential as an adjuvant in vaccines for infectious disease. “Adjuvant molecules that can increase the immunogenicity of antigens and modulate an enhanced immune response are essential components in human vaccine formulations,” said Dr. Vivanco Cid. “With so few licensed adjuvants for clinical use, characterization of new molecules is a high priority in the vaccination field. These preclinical data show that dtLLO is a safe and effective adjuvant molecule in vivo with the potential to stimulate a robust immune response required for prophylactic infectious disease vaccines.” Detoxified Listeriolysin O, or dtLLO, is Advaxis’ proprietary, nonhemolytic LLO developed by modifying the Listeria monocytogenes bacteria. In previous preclinical studies, dtLLO demonstrated potential efficacy as an adjuvant in tumor immunotherapy. dtLLO is an Advaxis technology with worldwide rights owned by the Company through a licensing agreement with the University of Pennsylvania. “These new preclinical data give us a better understanding of the immuno-stimulatory properties of dtLLO and how they can become an important component of vaccines for infectious diseases. The dtLLO adjuvant supported the generation of robust specific and diversified antibody responses, which is an important step in enhancing our infectious disease strategy and plan,” said Robert Petit, PhD, chief scientific officer of Advaxis. The data from these preclinical studies using dtLLO adjuvant in vaccine preparations targeting Dengue virus serotype 4 E protein, was published in the journal Clinical and Experimental Immunology. Advaxis intends to continue exploring the potential of dtLLO as an adjuvant molecule in the development of vaccines for infectious diseases. Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the European Medicines Agency's Committee for Advanced Therapies. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017. For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+. This press release contains forward-looking statements, including, but not limited to: statements regarding the completion and timing of the offering of shares. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov, as well as the risks identified or incorporated by reference in the registration statement and the prospectus supplement relating to the offering. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
Agency: Cordis | Branch: FP7 | Program: CP-FP-SICA | Phase: HEALTH.2012.3.4-1 | Award Amount: 7.41M | Year: 2013
Health services fragmentation is one of the main obstacles to effective health care in Latin-America, particularly for chronic diseases. This research builds upon results from Equity-LA (FP7-B-223123) and focuses on one of the most promoted policies to respond to fragmentation in LA, the development of Integrated Health Care Networks (IHN). The general objective is to evaluate the effectiveness of different care integration strategies in improving coordination and quality of care of IHN in different health care systems in Latin America, with particular reference to chronic diseases. Methods: The study adopts a quasi-experimental design, with a participatory action-research approach. In each country, two comparable IHN will be selected -one acting as the intervention and the other as the control area. It is structured in four phases: 1) a base-line study using qualitative and quantitative methods to carry out an initial evaluation of IHN performance; 2) design and implementation of an intervention focused on care coordination and quality of care; and based on health professionals training; 3) evaluation of effectiveness and limitations of interventions and associated contextual factors; and; 4) cross-country comparative analysis and elaboration of tools for getting research into policy. In each country, a research steering committee will be set up to lead the project, composed by health care professionals, managers, users and researchers. Results and relevance: The project will contribute to FP7 Cooperation Work Programme Health (SICA)s objectives by: 1) generating evidence-based policies to improve integration of care in Latin American countries; 2) strengthening research capacity of all involved institutions in order to enhance knowledge development on care integration in their countries; and by 3) contributing to skills improvement and motivation of health workforce, through training programs aimed at improving care coordination and quality.
Agency: Cordis | Branch: FP7 | Program: CSA | Phase: ICT-2011.3.4 | Award Amount: 466.09K | Year: 2011
The RISC project aims at deepening strategic R&D cooperation between Europe (EU) and Latin America (LA) in the field of High Performance Computing (HPC) by building a multinational and multi-stakeholder community that will involve a significant representation of the relevant HPC R&D EU and LA actors (researchers, policy makers, users). RISC will identify common needs, research issues and opportunities for cooperative R&D on HPC between EU and LA in the transition to multi-core architectures across the computing spectrum and relevant programming paradigms, algorithms and modelling approaches, thus setting the basis for the formulation of a global strategy for future research. The project will achieve its overall aim via a range of activities: 1. Assessing the ICT collaboration potential in the High Performance Computing and Computational Science area for the two regions; producing a Green Paper on High Performance Computing Drivers and Needs in Latin America; mapping the LA HPC actors and trends; identifying the opportunities for LA ICT actors in the EU and for EU HPC actors in LA; aligning EU and LA HPC policies and strategies; 2. Sharing and disseminating information and results in the focus area of EU HPC to a number of research, policy and practice actors dealing with technology applications in the LA region; making available existing Latin American HPC research to EU research, policy and practice actors;\n3.\tOrganising awareness-raising events about the ECs ICT R&D programmes, in particular those ones relevant to HPC and exascale computing for LA HPC actors. Organising Summer Schools and Advanced Workshops between EU and LA ICT actors to inform and initiate research collaborations between them. Networking, capacity building and training components of these events will enhance the impact 4. Actively engaging the relevant industry by focusing on industrial problems and problems with impact for the society. Providing advanced support services to a selected number of competent Latin American ICT actors to build long-term relationships with key EU counterparts. The target areas are: Innovation and HPC and its impact, Mathematical Models enhancing HPC and key areas such as Life Sciences, Climate Change, Financial Modelling etc with the corresponding research clusters concentrated around these areas.\n5.\tExtending HPC with links and relationships with complementary technology and tools in the areas of virtualization, data visualization, data analysis and simulation, aligned with industrial-driven application fields, creating a value chain for final users and practitioners. 6. Enhancing HPC R&D policy dialogue between policy makers and stakeholders from EU and Latin American HPC communities; develop a Road Map towards a Joint Strategy in HPC R&D. At the end of the project we expect a fully functioning network focusing on activities to support and to promote coordination of the HPC and Computational Science research between EU and LA.
Ortiz-Lozano L.,University of Veracruz
Ocean and Coastal Management | Year: 2012
Multiple steps are required to ensure compliance between Management of Marine Protected Areas in the Coastal Zone (MPACZ), and the objectives they were created for. Due to limited financial resources, there is an emerging necessity to identify priority actions that impact efficiently in the conservation objectives of the protected area. A simplified causal network analysis of the environmental problems of MPACZ is proposed in this paper as a tool for identifying those priority actions. This paper shows that management of an MPACZ is a complex task influenced by the origin and spatial location of the causes of environmental issues affecting it; the example case is the Sistema Arrecifal Veracruzano National Park in Mexico. Through the identification of 17 environmental problems and 50 causes that generate them, it was found that environmental impacts within a protected area may be due to many causes, whether human or natural, and that the choice of priority actions should be made considering causal relationships between them to achieve efficient use of available financial resources. © 2011 Elsevier Ltd.
De La Herran-Arita A.K.,Stanford University |
Garcia-Garcia F.,University of Veracruz
Drugs | Year: 2013
Narcolepsy/hypocretin deficiency (now called type 1 narcolepsy) is a lifelong neurologic disorder with well-established diagnostic criteria and etiology. Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness (EDS) and symptoms of dissociated rapid eye movement sleep such as cataplexy (sudden loss of muscle tone), hypnagogic hallucinations (sensory events that occur at the transition from wakefulness to sleep), sleep paralysis (inability to perform movements upon wakening or sleep onset), and nocturnal sleep disruption. As these symptoms are often disabling, most patients need life-long treatment. The treatment of narcolepsy is well defined, and, traditionally, amphetamine-like stimulants (i.e., dopaminergic release enhancers) have been used for clinical management to improve EDS and sleep attacks, whereas tricyclic antidepressants have been used as anticataplectics. However, treatments have evolved to better-tolerated compounds such as modafinil or armodafinil (for EDS) and adrenergic/serotonergic selective reuptake inhibitors (as anticataplectics). In addition, night-time administration of a short-acting sedative, γ-hydroxybutyrate (sodium oxybate), has been used for the treatment for EDS and cataplexy. These therapies are almost always needed in combination with non-pharmacologic treatments (i.e., behavioral modification). A series of new drugs is currently being tested in animal models and in humans. These include a wide variety of hypocretin agonists, melanin-concentrating hormone receptor antagonists, antigen-specific immunopharmacology, and histamine H3 receptor antagonists/inverse agonists (e.g., pitolisant), which have been proposed for specific therapeutic applications, including the treatment of Alzheimer's disease, attention-deficit hyperactivity disorder, epilepsy, and more recently, narcolepsy. Even though current treatment is strictly symptomatic, based on the present state of knowledge of the pathophysiology of narcolepsy, we expect that more pathophysiology-based treatments will be available in the near future. © 2013 Springer International Publishing Switzerland.
Arteaga-Vazquez M.A.,University of Veracruz
Current Biology | Year: 2016
The genetic and molecular basis of the developmental programs underlying adaptive morphological changes is largely unknown. A new study reveals an ancient gene that has been instrumental for the generation of morphological diversity and adaptation in land plants. © 2016 Elsevier Ltd.
Lerma H. S.,University of Veracruz |
Dukelsky J.,CSIC - Institute for the Structure of Matter
Nuclear Physics B | Year: 2013
The Lipkin-Meshkov-Glick (LMG) model has a Schwinger boson realization in terms of a two-level boson pairing Hamiltonian. Through this realization, it has been shown that the LMG model is a particular case of the SU(1, 1) Richardson-Gaudin (RG) integrable models. We exploit the exact solvability of the model to study the behavior of the spectral parameters (pairons) that completely determine the wave function in the different phases, and across the phase transitions. Based on the relation between the Richardson equations and the Lamé ordinary differential equation we develop a method to obtain numerically the pairons. The dynamics of pairons in the ground and excited states provide new insights into the first, second and third order phase transitions, as well as into the crossings taking place in the LMG spectrum. © 2013 Elsevier B.V.
Cuevas-Cordoba B.,University of Veracruz |
Santiago-Garcia J.,University of Veracruz
OMICS A Journal of Integrative Biology | Year: 2014
Saliva is a fluid that can be collected easily and noninvasively. Its functions in the oral cavity are well known. Advances in molecular biology and technology, as well as research conducted by the various disciplines of omics (genomics, transcriptomics, proteomics, metabolomics, and metagenomics) have contributed to the identification and characterization of salivary components, including DNA, RNA, proteins, metabolites, and microorganisms. These biomolecules enter the saliva through extracellular and intracellular routes, providing information from several organs and systems and raising the possibility of their use as disease biomarkers. In recent years, these factors have expanded the potential use of saliva as a diagnostic fluid for oral and systemic diseases. This review integrates information regarding salivary biomolecules studied through omics and explores their utility as biomarkers for the diagnosis of several infectious and noninfectious diseases, and the opportunity they represent for the development of point of care devices for clinical application. We also discuss the advantages, disadvantages, and challenges to be overcome in order to establish saliva as a useful fluid for the accurate diagnosis and monitoring of a wide range of diseases. © Copyright 2014, Mary Ann Liebert, Inc. 2014.
Shmaliy Y.S.,University of Guanajuato |
Morales-Mendoza L.J.,University of Veracruz
IEEE Transactions on Signal Processing | Year: 2010
We address a smoothing finite impulse response (FIR) filtering solution for deterministic discrete-time signals represented in state space with finite-degree polynomials. The optimal smoothing FIR filter is derived in an exact matrix form requiring the initial state and the measurement noise covariance function. The relevant unbiased solution is represented both in the matrix and polynomial forms that do not involve any knowledge about measurement noise and initial state. The unique l-degree unbiased gain and the noise power gain are derived for a general case. The widely used low-degree gains are investigated in detail. As an example, the best linear fit is provided for a two-state clock error model. © 2006 IEEE.
Gonzalez-Gaudiano E.J.,University of Veracruz
Journal of Environmental Education | Year: 2016
In light of the challenging developmental issues confronting the countries of Latin America, this response article analyzes the power and resistance of education for sustainable development from both theoretical and policy perspectives. Of particular concern are the neo-productivist strategies driving the latest stage of capitalist development. This needed discussion about education and development fluctuates between necessity and contingency. Derrida's concept of the "constitutive outside" accounts for how existing tensions within education for sustainable development inform the need for new identification models that are open, unsteady, incomplete, and relational. The constitutive outside also recovers the notion of "tragic optimism" (Santos, 2009) for clarifying the complexity of the struggle for emancipation and the confidence of the human capacity to create horizons of possibility. This confidence and capacity cannot be objectified from the impossible discourse (and palimpsest) of the texts/policies of education for sustainable development. © 2016 Taylor & Francis Group, LLC.